Ann: Admedus update on TAVR project, page-15

US companies, like where WP has worked, traditionally have an under promise over deliver culture which is a mantra I believe WP follows also. He has proven this by beating the revenue target that were set previously for 2017/2018 ($22.3m v forecasts of $21.2 m from memory)
When he says he expects a TAVR deal in 6-12 months you better believe he is working day and night to make that happen in 6 months if not sooner. If we start the clock at the AGM in November 2017 then 6 months brings us to May 2018. As we know we have our AGM in May 2018, WP would no doubt love to return in May with a TAVR deal and show once and for all our transition from a pharma to a global medtech is complete. The VAX deal and TAVR deal will be important symbolic milestones in addition to the obvious financial ones as it completes the renaissance of Admedus from old management to new, old company to new and releases the shackles and sins of prior management which we have been dragging like a ball and chain. WP and team are painting a masterpiece, some can see its beauty taking shape, some are still skeptical but come the AGM I have a feeling everyone, skeptics included, will sit back and marvel and say 'ahhhhh now I see it!' Good luck to all and keep the faith, we have quality products and quality people.